Introduction: Moqlenjan supplement plays an important role in the treatment and prevention of dyslipidemia and diabetes and may increase the benefits of exercise. This study was conducted to examine the effect of aerobic training with Moqlenjan supplementation on lipid profiles and glycemic indices of overweight men. Methods: In this clinical study, 32 overweight men in the age range of 35 to 45 years old and BMI 26.93±1.3 kg.m-2 were randomly divided into four groups of eight: 1) aerobic training, 2) Moqlenjan supplement, 3) aerobic training along with the Moqlenjan supplementation 4) control. Groups 1 and 3 performed aerobic exercise 60-80% of maximum heart rate for eight weeks, three sessions per week, and each session for 40 to 50 minutes. Also, groups 1 and 3 consumed two 250 mg tablets per day for eight weeks. Before the start of the study and 48 hours after the last training session, the variables of the research were measured from all the groups. For data analysis, SPSS software version 21 was used for statistical analysis of variance analysis and paired sample t-test. The significance level of the tests was less than 0.05. Results: Aerobic training, supplementation and aerobic training along with supplementation caused a significant decrease in fat, triglyceride, cholesterol, LDL, and insulin resistance, and a significant increase in HDL (P≤0.05), but did not change the weight and body mass index (P> 0.05). The results also showed that aerobic training along with supplementation has more effect on the above variables than aerobic training and supplement alone. Conclusion: It seems that aerobic training along with Moqlenjan supplement results in a higher reduction in the percentage of fat, triglyceride, cholesterol, LDL, and insulin resistance, as well as a higher increase in the HDL in comparison with aerobic training exercise and supplementation alone.
Therefore, it is recommended that these people use aerobic training with Moqlenjan supplement to lower blood lipids, improve insulin resistance, and prevent diabetes. Manuscript profile